Aethlon Medical(NASDAQ:AEMD) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-hours on Jun 29, 2016. Company reported revenue of $204.66K. Analysts estimated a revenue of $1.50M. Earnings per share were $-0.16.
Aethlon Medical (AEMD) made into the market gainers list on Fridays trading session with the shares advancing 5.96% or 0.34 points. Due to strong positive momentum, the stock ended at $6.04, which is also near the day’s high of $6.0499. The stock began the session at $5.78 and the volume stood at 14,599 shares. The 52-week high of the shares is $12.25 and the 52 week low is $4.02. The company has a current market capitalization of $46 M and it has 76,22,393 shares in outstanding.
Aethlon Medical Inc. is a medical device company which creates medical devices to address unmet therapeutic needs in infectious disease cancer and other life-threatening conditions. The Company’s lead product is the Aethlon Hemopurifier which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications the Hemopurifier targets the removal of circulating exosomes which are secreted by tumors to prevent the immune system from rejecting the tumors. Through its subsidiary Exosome Sciences Inc. (Exosome) the Company is also developing exosome-based products to diagnose and monitor neurological disorders and cancer. Additionally the Company operates under two Department of Defense contracts related to a program entitled Dialysis-Like Therapeutics.